- Conditions
- COVID-19
- Interventions
- Acalabrutinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 31
- States / cities
- Anniston, Alabama • Mobile, Alabama • Escondido, California + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 42
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Acalabrutinib, Obinutuzumab, Chlorambucil
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 51
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 44 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 28 more
- Conditions
- Hepatic Impairment, Hepatic Insufficiency, Healthy Subjects
- Interventions
- acalabrutinib
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Knoxville, Tennessee
- Conditions
- Ovarian Cancer
- Interventions
- Acalabrutinib, acalabrutinib and pembrolizumab combination
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Philadelphia, Pennsylvania
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- acalabrutinib, rituximab (IV), Lenalidomide
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Downey, California • Duarte, California + 18 more
- Conditions
- Healthy Participants
- Interventions
- ACP-196, Calcium carbonate, Omeprazole, Rifampin
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Waldenström Macroglobulinemia (WM)
- Interventions
- Acalabrutinib (ACP-196)
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 10
- States / cities
- Santa Barbara, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- pembrolizumab, Acalabrutinib
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- ACP-196, ACP-196 in combination with pembrolizumab
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- NHL, DLBCL, Non-hodgkin's Lymphoma, Diffuse Large B Cell Lymphoma
- Interventions
- AZD9150, Acalabrutinib, AZD6738, Hu5F9-G4, Rituximab, AZD5153
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 7 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- ACP-196 (acalabrutinib)
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Concord, California • La Jolla, California + 12 more
- Conditions
- Healthy Volunteers
- Interventions
- Acalabrutinib, Microtracer [14C]ACP-196
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lymphoma, Mantle Cell
- Interventions
- Acalabrutinib, Bendamustine, Rituximab, Placebo
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Downey, California • Santa Monica, California + 27 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Acalabrutinib, Ibrutinib
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Anaheim, California • Berkeley, California + 26 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
- Interventions
- acalabrutinib, Obinutuzumab, Venetoclax, Rituximab
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Acalabrutinib
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- ACP-196, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 10
- States / cities
- Ventura, California • Fort Myers, Florida • Durham, North Carolina + 6 more
- Conditions
- Mantle Cell Lymphoma (MCL)
- Interventions
- ACP-196 (acalabrutinib)
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Chicago, Illinois • Niles, Illinois + 6 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- ACP-196
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 2 more
- Conditions
- Healthy Volunteers
- Interventions
- ACP-196, Omeprazole
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Infectious Disease
- Interventions
- Acalabrutinib, Rabeprazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
- Interventions
- Acalabrutinib
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Bendamustine, Rituximab, Acalabrutinib, Cytarabine, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri